Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4388741 | 0.76 | TDP1 (0.54) | TDP1HTTCYP11B1CYP11B2POLB | |
| SCHEMBL7196401 | 0.75 | TDP1 (0.58) | TDP1HTTCYP11B1CYP11B2POLB | |
| SCHEMBL11706281 | 0.74 | TDP1 (0.52) | TDP1HTTCYP11B1CYP11B2POLB | |
| SCHEMBL2489876 | 0.73 | TDP1 (0.56) | TDP1HTTCYP11B1CYP11B2POLB | |
| SCHEMBL8668369 | 0.71 | TDP1 (0.54) | TDP1HTTCYP11B1CYP11B2POLB | |
| SCHEMBL145442 | 0.71 | TDP1 (0.54) | TDP1HTTCYP11B1CYP11B2POLB | |
| SCHEMBL5399 | 0.71 | TDP1 (0.59) | TDP1HTTCYP11B1CYP11B2POLB | |
| SCHEMBL278161 | 0.71 | TDP1 (0.54) | TDP1HTTCYP11B1CYP11B2POLB | |
| SCHEMBL277760 | 0.71 | TDP1 (0.54) | TDP1HTTCYP11B1CYP11B2POLB | |
| SCHEMBL9062626 | 0.71 | TDP1 (0.54) | TDP1HTTCYP11B1CYP11B2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108640878-A | A kind of BenzoiminazoleflouriAnd class compound and its preparation method and application | 上海泰坦科技股份有限公司 | 2018-10-12 | — | — | CN | claimed |
| US-20260125376-A1 | IRREVERSIBLE INACTIVATORS TARGETING ARAF/MEK COMPLEXES | GERO THOMAS (US) | 2026-05-07 | — | — | US | disclosed |
| CN-120172974-A | 1-Fluorobenzimidazole pyridine derivative and preparation method and application thereof | 淮阴师范学院 | 2025-06-20 | — | — | CN | disclosed |
| CN-120172974-A | 1-Fluorobenzimidazole pyridine derivative and preparation method and application thereof | 淮阴师范学院 | 2025-06-20 | — | — | CN | disclosed |
| US-20220403229-A1 | ELECTRONIC CONTROL OF TRANSMITTANCE OF VISIBLE AND NEAR-INFRARED RADIATION | KEBOTIX, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| CN-115350179-A | Application of fluorobenzimidazole thiosemicarbazide compound in antitumor drugs | 青岛科技大学 | 2022-11-18 | — | — | CN | disclosed |
| CN-109071508-A | Benzimidazole bis-indole compound as novel divalent IAP antagonist | 南京明德新药研发股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-107312056-A | The synthetic method of 2 (the pregnane base of 3 ' hydroxyl 17 ') 5 fluorobenzimidazoles | 广西师范学院 | 2017-11-03 | — | — | CN | disclosed |
| US-9382226-B2 | Aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| CN-105142623-A | Methods and compositions for improving cognitive function | AGENEBIO INC | 2015-12-09 | — | — | CN | disclosed |
| WO-2012012478-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
| EP-2298770-A1 | Heterocyclic compounds as TrkA modulators | ChemBridge Corporation (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20090105400-A1 | Imidazolium side chains for example; for example polymers based on 1-methyl-3-(2H,9H,9H-perfluoro-3,6-dioxa-5-methyl-8-nonenyl)-imidazolium trifluoromethanesulfonate; polymer electrolytes for fuel cell, secondary battery, capacitor, dye-sensitized solar cell and electrochromic device | DAIKIN INDUSTRIES, LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090069343-A1 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus | DUNFORD PAUL J | 2009-03-12 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| EP-1960382-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | ChemBridge Research Laboratories, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| CN-1784387-A | Novel benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | disclosed |
| US-5118506-A | Mixing with baits in solid or liquid forms which acts as a poison to kill fire ants by ingestion or by respiratory contact; nontoxic to human and animal | Casella, Peter F. (US) | 1992-06-02 | — | — | US | disclosed |
| US-4891222-A | AQUEOUS EMULSION, NONIONIC AND ANIONIC SURFACTANTS | TFA PRODUCTS, INC | 1990-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125376-A1 | IRREVERSIBLE INACTIVATORS TARGETING ARAF/MEK COMPLEXES | ARAF, BRAF, RAF1 | TDP1 2570/4885HTT 3759/4885CYP11B1 3242/4885 |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | TDP1 1277/4885HTT 2486/4885CYP11B1 913/4885 |
| US-20090069343-A1 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus | HRH4, HRH2, HRH3 | TDP1 3094/4885HTT 563/4885CYP11B1 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.